Teva pharmaceuticals has issued a voluntary recall of one lot of its reflux medication after discovering that bottles contained tablets of a drug used to treat fluid retention. The recall affects lot ...

Am J Health Syst Pharm. 2012;69(2):116-124. The clonidine patch is one example of a TDDS offering several of those benefits. Clonidine patches are applied once every seven days, allowing a reduced ...

f Telephone communication with Erika M, medical information department, Teva Pharmaceuticals, 2011 May 26. g Telephone communication with Lori Stone, medical information department, King ...

The guidelines focuse on two weight management medications that have shown superior effectiveness: semaglutide (a GLP-1 receptor agonist) and tirzepatide (a GLP-1/GIP receptor agonist).

Middlesex County Popular ‘miracle’ weight loss drug is causing people to lose their vision, lawsuits claim Published: Jun. 19, 2025, 11:00 a.m.

During this hurricane season and for those to come, DePaul Community Health Center officials say they are making patients’ health and overall wellness a priority. Adequate and affordable ...

Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical (Fosun Pharma) have announced a strategic partnership focused on developing a drug candidate currently in phase 1 clinical development ...

[READ: Exercising on GLP-1s: How to Stay Safe and Healthy] Weight Loss Drugs and Long-Term Success When treating obesity, success isn’t all about losing weight.

The medication was apparently distributed to three states: Illinois, Mississippi, and Pennsylvania. Icosapent ethyl can be “used together with a proper diet to help control high triglyceride (fat-like ...

From the midpoint of 2015 through late 2023, Teva stock lost close to 90% of its value due to a number of headwinds: Its blockbuster multiple sclerosis drug Copaxone lost its sales exclusivity.

Teva and Fosun Pharma join forces to develop TEV-56278, a promising cancer therapy. Read more here.

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Provided by GlobeNewswire Jun 16, 2025, 5:30:00 AM ...